

INDEX

- abnormal behavior, and diagnostic thresholds, 66
- abulia, and overmedication, 107
- acronyms, and marketing of medical conditions, 135
- adolescents, and antidepressants, 198–99, 205–6
- Adult Anxiety Clinic, Temple University, 7, 136
- advertising: by drug companies, 105, 106–17; for Paxil, 105, 121–34. *See also* marketing, pharmaceutical
- advocacy groups, and marketing, 136–37
- agoraphobia, 15, 30, 42, 71–72, 76
- Akiskal, Hagop, 27
- alizarin (mordant red), 37
- American Psychiatric Association (APA): archives, 6; biomedical emphasis of, 104; and *DSM-III*, 2–3, 39–42, 47–48; and *DSM-III* Task Force on Nomenclature and Statistics, 42–47, 51–56; and *DSM-III-R*, 97; maintaining *DSM* categories, 202; and marketing of social anxiety disorder, 123, 125
- American Psychoanalytic Association, ad hoc committee on *DSM-III*, 54–55
- Amitriptyline hydrochloride, as tricyclic antidepressant, 106
- anger, expression of, and social anxiety disorder, 162, 163, 164, 166. *See also* intermittent explosive disorder (IED)
- anticholinergic drugs, 142, 146–47, 174. *See also* Paxil (paroxetine hydrochloride)
- antidepressants: for children and adolescents, 198–99, 205–6; and emotional blunting, 8; marketing of, 4, 17, 106–17, 121; risks of, 117–18, 198; for social anxiety disorder, 120–21. *See also* Paxil (paroxetine hydrochloride); selective serotonin-reuptake inhibitors (SSRIs)
- antisocial behavior, and conformism, 245–46ⁿ⁴²
- Antisocial Behaviour Orders (ASBOs in Britain), 207, 245ⁿ⁴²
- antisocial personality disorder (ASPD), 15–16, 17
- anxiety: causes and effects of, 19–20, 149–53; drug treatments for, 140–41, 151, 161, 166–68; and expression of anger, 162–63; Freudian views of, 31–35, 154–55, 157, 160; historic views of, 8, 9, 11–14; and marketing of Paxil, 121; as rational response to stress, 139, 168; sociological perspectives of, 155–61
- anxiety disorders: and “chemical imbalance,” 159; drug treatments for, 105, 139; Freudian view of, 32–34; and marketing campaigns, 134–38; naming and

- anxiety disorders (*continued*)
 diagnostic categories of, in *DSM-III*, 54, 67, 76, 78–79, 92–97, 195; psychodynamic approaches to, 54; statistical percentages for, 199, 213*n*1. *See also* anxiety neurosis
- Anxiety Disorders Association of America, 123, 125
- Anxiety Disorders clinics, 4, 69
- anxiety neurosis: *DSM-II*, 42–43, 72; *DSM-III*, 46, 56, 75–76; Feighner criteria for, 62; Freudian view of, 32, 154–55
- anxiolytics, as drug treatment for anxiety, and Paxil, 121
- apathy, as “mental disorder,” 194, 199, 204, 208–9
- Arnstein, Robert, 90
- AstraZeneca pharmaceutical company, 119
- attention deficit hyperactivity disorder (ADHD), 135
- avoidant personality, and social anxiety, 87, 88, 158, 202
- avoidant personality disorder (APD), 1; and cultural noncompliance, 9, 168, 207; and *DSM-III*, 56, 74, 78–79, 92, 94–97, 114; and *DSM-IV*, 97; and marketing campaigns, 8, 114; and psychiatric diagnosis, 163
- Ayd, Frank, *Recognizing the Depressed Patient*, 106
- Barlow, David, 27, 69
- Bayer, Ronald, 59, 63
- Beckett, Samuel, *Endgame*, 211
- Bell, Charles, 29
- Berk, Howard, 64, 65
- Beyond Therapy* (U.S. government report), 209
- binge-eating disorder, 195
- biology: and mental disorders, 19–20, 21, 63–64, 205; and perceptions of anxiety, 149–53
- blood-clotting problems, as side effect of anticholinergics, 118, 120
- blushing: and anxiety, 29–30; and social phobia, 71
- Braff, Zach, *Garden State* (film), 9, 182–85, 188
- brain: and biomedical perspectives on mental disorders, 2, 19–20, 21, 206; chemistry of, and drug treatment, 20, 146–49, 151, 205–7, 208; and consciousness, 149, 153. *See also* neuropsychiatry; pharmacology; psychopharmacology
- Brand, Barry, 105, 106
- Brecher, Martin, 119
- Britain, and ASBOS, 207, 245*n*40
- Burgess, Thomas, 29
- Burton, Richard, *The Anatomy of Melancholy*, 12, 26–27
- Caldwell, Anne, 106
- Canada, as source for prescription drugs, 203, 204
- Carroll, Lewis, *Alice in Wonderland*, 58–61 *passim*
- Cassels, Alan, with Ray Moynihan, *Selling Sickness*, 112, 123, 136
- Chaleby, Kutaiba, on social phobia in Saudi Arabia, Britain, 17–18
- Chappell, Ann, 85–86
- childhood disorder, 88
- children: danger of SSRIs to, 118–19, 142; general drug treatments for, 168, 198–99, 234–35*n*41
- chlorpromazine (Thorazine/Largactil), 37, 170, 191
- Chodoff, Paul, 64
- cholinergic system, 146–49, 151
- chronic, as term, and *DSM* diagnostic criteria, 62
- chronic anxiety, 8, 205
- chronic complaint disorder, 67
- chronic hypomanic disorder, 82
- chronic undifferentiated unhappiness, 67
- Ciba pharmaceutical company, 37
- Clark, David M., 7
- cognitive-behavior therapy, 141, 162–66, 168
- Cohn and Wolfe, public relations firm, 117; and behind-the-scenes funding for sup-

- port groups, 125, 137; and marketing of Paxil, 121–34
- Collegium Internationale Neuropsychopharmacologium (CINP), 37
- compulsive buying, as mental disorder, 195, 199, 204
- compulsive sexual behavior, as mental disorder, 195
- consciousness: and drug treatment, 151, 153; role of, in mental illness, 206; and temperament, 149
- Corrections, The* (Franzen), 9, 172–82, 185, 188
- “cosmetic psychopharmacology” (Kramer), 16–17, 101, 171–72, 195
- Cottle, Michelle, 135–36
- Crowley, Ralph, 78–79
- culture: and diagnostic categories, 18; and social adaptation, 207–8, 209–10
- Darwin, Charles: on anxiety, 20; *Descent of Man*, 29; *The Expression of the Emotions in Man and Animals*, 14, 29, 47, 48, 219n46; and shyness as adaptive trait, 29–30; and social anxiety, 28
- dating anxiety, 7, 136
- daydreaming, 89
- DeLillo, Don, *White Noise*, 172
- Depakote (divalproex sodium), 171
- depression: drug treatments for, 153; and marketing of drugs, 106–17, 120–21, 134–35; side effects of medication, 117–21, 142–49
- Deprol (meprobamate), drug treatment for depression and anxiety, 111
- De Quincey, Thomas, *Confessions of an English Opium Eater*, 169
- Diagnosis, The* (Lightman), 9, 185–88, 190, 244n32
- diagnostic criteria, and *DSM-III*, 24, 38, 56–69, 201–2
- diagnostic testing, as marketing device, 135–36
- diagnostic thresholds, and abnormal behavior, 66
- Dickens, Charles, *Little Dorrit*, 219n47
- Dickinson, Emily, 8, 9
- dimethylamines, 37
- disorder, as term with biological connotations, 56. *See also* mental disorders
- Dobson, Roger, 207
- Dr. Mukti and Other Tales of Woe* (Self), 9, 188–93
- drug companies: advocacy groups and charities, funding for, 135–37; cultural backlash against, 172–77; and FDA, 112, 114, 229n72; guidelines and medical inventories established by, 135–36; marketing of antidepressants, 13–14, 37, 106–17; marketing of mental illness, 13–14, 43, 101–3, 104, 137, 199; relationship with American psychiatry, 104, 114, 202–4; and research funding, 73–75; and side effects, 119; and ties to *DSM*, 3, 6, 37, 104, 114, 120–21
- drug treatment: and brain chemistry, 20, 146–49, 151, 205–7, 208; for children and adolescents, 118–19, 142, 168, 198–99, 234–35n9; and emotional blunting, 107, 151, 182, 238n28; and managed health care, 194, 197–98, 221n5; and neuropsychiatry, 35–37, 104, 153, 162, 194; and rebound syndrome, 139–41, 148; withdrawal symptoms from and side effects of, 117–21, 141–49
- DSM* (*The Diagnostic and Statistical Manual of Mental Disorders*): and pharmaceutical industry, 3, 6, 37, 104, 114, 120–21; revisions to and expansion of, 2–3, 4, 6, 37, 202
- DSM-I* (1952), 36–37, 38, 80, 91, 170
- DSM-II* (1968): diagnostic categories of, 38, 40, 41–42, 75, 92; and *ICD-8*, 37–38; and personality disturbances, 80; and “schizoid” as term, 80, 88, 91
- DSM-III* (1980): and advocacy groups, 136; antipsychoanalytic bias of, 3, 25–28, 46–56, 60–61; and avoidant personality disorder (APD), 56, 74, 78–79, 92, 94–97, 114; diagnostic criteria of, 24, 38, 56–69, 201–2; general expansion of disorders in, 2–3, 37, 68–70, 92–97,

DSM-III (1980) (*continued*)

120–21, 139, 141; inclusion of panic disorder and social phobia in, 17, 50, 71–78, 97–98, 100, 208; and intermittent explosive disorder (IED), 15, 195; and introverted personality disorder (IPD), 78, 79–91; premenstrual dysphoric disorder (PMDD), 82, 195; publication of, 47–51; redefinition and expansion of anxiety disorders in, 92–97, 120–21; and schizoid personality disorder (SPD), 9, 80, 81, 88, 91, 97, 202; selection and description of new disorders, 41–47, 51–56, 202; and task force politics, 39–42, 46–47, 58–61, 222n17

DSM-III-R (1987), 43, 44, 202; diagnostic criteria for, 191; and social phobia/social anxiety disorder, 83, 96, 97–101

DSM-IV (1994), 3, 15; diagnostic criteria for, 197, 200–201, 202; and premenstrual dysphoric disorder (PMDD), 82, 195; recalibration of anxiety disorders in, 43, 97–101, 104; satire of, in *Dr. Mukti and Other Tales of Woe* (Self), 191–93; and social anxiety disorder, 76, 97–101

DSM-V, likely diagnostic criteria for, 194–202

DTC (direct-to-customer) marketing, 112, 132

Duffy, James, 194, 204

Effexor (venlafaxine), 147, 196

Elder, Ivan, 90

Eli Lilly pharmaceutical company, 117, 120, 173

emotional blunting, from antidepressants, 8, 107, 151, 182, 238n28

emotions, human, medicalization of, 8, 195, 208–11

Endicott, Jean, 45

erectile dysfunction (ED), 135, 195

Erwin, Brigitte, on social anxiety disorder, 162–66

European Medicines Agency (EMA), 121

extroversion: and *DSM-III*, 82; cultural expectation of, 209

Faust, David, 70

Feighner, John, 62

Feighner criteria, and diagnosis, 62

Feinstein, Alvan, on psychiatric diagnosis, 58–59

Fink, Paul, 47

Finney, Joseph, 90

Food and Drug Administration, U.S. (FDA): approval of Paxil to treat social anxiety disorder, 121, 122, 125–26, 139; approval of SSRIs in general, 1–2, 118; and conflicts of interest, 114, 119, 229n72; and marketing of Paxil, 120, 121, 122, 137; and pharmaceutical advertising, 111–12

Food, Drug, and Cosmetic Act (1938), 1962 amendment to, 111

Forman, Janet, 90–91

Frances, Allen, 42, 88, 95, 96

Franzen, Jonathan, *The Corrections*, 9, 172–82, 185, 188

Freedom From Fear (FFF), 123, 125, 132, 136

Freud, Sigmund: on anxiety, 19, 32–35, 141, 154–55, 157, 160–61, 165, 168; and biomedicine, 26, 32, 166; *Civilization and Its Discontents*, 34–35, 161, 188; concept of normal behavior, 27; *The Ego and the Id*, 160–61; and Emil Kraepelin, 21, 24; and the “estrangement” between the somatic and the psychical, 32; on the form and speed of treatment, 33–34, 154–55, 165; *Inhibitions, Symptoms and Anxiety*, 34; “The Justification for Detaching from Neurasthenia a Particular Syndrome: The Anxiety-Neurosis,” 32–33; *Project for a Scientific Psychology*, 31–32; on the superego as a cause of anxiety, 34–35, 160–62; and systemic suffering, 205; “‘Wild’ Psychoanalysis,” 154–55, 165. *See also* psychoanalysis

Freudian psychoanalysis, and perspective of *DSM-III*, 25–26, 46–47, 53–54, 75, 76

Friedan, Betty, 93

Frosch, John, 59–60, 61

Frosch, William, 50, 55, 60, 61

- Garden State* (film), 9, 182–85, 188
- Garfinkel, Renee, 45
- Gates, David, 169, 181
- Geigy pharmaceutical company, 37
- Gelder, Michael, and *DSM-III* inclusion of social phobia, 71–72
- generalized anxiety disorder (GAD), 69, 76, 120, 163
- GlaxoSmithKline (UK), and health risks of Paxil, 117–19, 139–49, 234–35ⁿ⁴¹. *See also* Smith, Kline and French; Smith-Kline Beecham
- Gondry, Michel, with Charlie Kaufman, *Eternal Sunshine of the Spotless Mind* (film), 172
- Graduate, The* (film), 184
- Greist, John H., with James W. Jefferson and David J. Katzelnick, *Social Anxiety Disorder: A Guide*, 4, 20
- Griesinger, Wilhelm: *Mental Pathology and Therapeutics*, 21, 29; and normal behavior, 27, 32; and scientific psychiatry, 21, 24, 63
- Grinspoon, Lester, 47, 64
- Group for the Advancement of Psychiatry, 36–37
- Guardino, Mary, 130, 132
- Guze, Samuel, 61, 62
- Hall, James, 91
- Hardy, Thomas, *The Mayor of Casterbridge*, 165–66
- Hartenberg, Paul, *Les Timides et la timidité*, 30–31, 219ⁿ⁵²
- Hawkins, Beth, 112
- Hawthorne, Nathaniel, and his “philosophy of shyness,” 8, 9
- healthcare system, U.S.: and *DSM*, 3, 40; and escalating cost of drug treatments, 197–98
- health charities, funding of, 136–37
- Healy, David, 43, 198; *The Antidepressant Era*, 25, 73; on categorical distinctions in *DSM-III*, 69, 75–76, 199; on drug treatments for children, 198; on perspective of *DSM-III*, 50; on regulation of drug companies, 114; on side effects of Paxil, 7, 118, 119; on social phobia/social anxiety disorder, 71, 73, 93, 101
- Heimberg, Richard, 7, 94, 136; on social anxiety disorder, 162–66
- Henderson, Lynne, 5
- Hippocrates, and contemporary interpretations of earlier forms of anxiety and shyness, 12, 13, 14, 15
- homosexuality, and *DSM-II* and *DSM-III*, 41–42, 221–222ⁿ¹⁴
- human emotions, medicalization of, 8, 195, 208–11
- Hussey, Andrew, 209
- Huxley, Aldous, *Brave New World*, 169–70, 182
- Hyler, Steven E., 67, 89–90
- Hynes, James, 187–88
- insurance companies, and *DSM* diagnosis, 3
- intermittent explosive disorder (IED), 7, 15, 163, 195. *See also* road rage
- International Classification of Diseases (ICD)*, and updating of *DSM*, 3, 37–38, 41, 50–51, 81
- Internet addiction, as mental disorder, 195, 199
- introspection, 82, 158, 168
- introversion, cultural view of, 158, 207–9
- introverted personality disorder (IPD), evolution of, and *DSM-III*, 9, 66–67, 78–91
- Janet, Pierre, and social phobia, 30, 71
- Janssen pharmaceutical company, 119
- Janulis, Peter, 48, 49
- Jaso, Hector, 64, 65
- Jefferson, James W., with John H. Greist and David J. Katzelnick, *Social Anxiety Disorder: A Guide*, 4, 20
- Jenner, Paul N., 119–20
- Johnson, Ken, executive vice president, *PhRMA*, 204
- Johnson and Johnson pharmaceutical company, 136
- Jung, Carl, 79
- Jungians, and *DSM-III* classification of introversion, 79–89 *passim*

- Kakutani, Michiko, 174
- kappa index of reliability, and *DSM-III*, 68, 69
- Katzelnick, David J., with John H. Greist and James W. Jefferson, *Social Anxiety Disorder: A Guide*, 4, 20
- Kaufman, Charlie, with Michel Gondry, *Eternal Sunshine of the Spotless Mind* (film), 172
- Keizer, Garret, 210
- Kernberg, Otto, 50
- Kesey, Ken, *One Flew over the Cuckoo's Nest*, 40
- Kessler, Ronald, and retention of mild disorders in *DSM*, 195–202, 204
- kidney failure, as side effect, and Paxil, 118, 120, 142
- Kierkegaard, Søren, *The Concept of Anxiety*, 16
- Kirk, Stuart A., with Herb Kutchins, 68–69; *Making Us Crazy*, 4, 201
- Kirsch, Thomas, 82
- Klein, Donald, 42, 94; and avoidant personality disorder, 74, 92–93, 95, 96; and descriptive diagnosis, 36, 44, 63–64, 205; and “introversion” as term, 79, 87, 88, 90
- Kleinman, Arthur, 18, 199–200, 204
- Klerman, Gerald, 63, 96
- Kraepelin, Emil, 32, 35–36, 44, 166; and Alzheimer's disease, 177; biological perspective of, 21–28, 218*n*32; and diagnostic criteria of *DSM-III*, 61, 63, 64; *Lectures on Clinical Psychiatry*, 22, 23
- Kramer, Peter D., 78, 233*n*27; *Against Depression*, 233*n*27; and “cosmetic psychopharmacology,” 17, 195; *Listening to Prozac*, 169–72, 175, 177
- Kutchins, Herb, with Stuart Kirk, 68–69; *Making Us Crazy*, 4, 201
- Laughren, Tom, 119
- Le Carré, John, *The Constant Gardener*, 172
- Lehrman, N. S., 46, 59, 73–74
- leukotomy, 206
- Lewis, C. S., *The Chronicles of Narnia*, 181
- Lewis, Sir Aubrey, and *ICD-8*, 38
- Lexapro (escitalopram oxalate), 147
- Librium (Chlordiazepoxide), 106
- Liebowitz, Michael, 7; on psychoanalytic theory, 27; on public speaking anxiety, 100–101; and social phobia/social anxiety disorder, as *DSM* category, 7, 93–101 *passim*
- Liebowitz Social Anxiety Scale, 102–3
- Lightman, Alan: *The Diagnosis*, 9, 185–88, 190, 244*n*32; *Einstein's Dreams*, 185
- Lion, John, 86–87, 92, 95–96
- lithium, 171
- MacKinnon, Roger, 89, 95, 202
- Madow, Leo, chair, liaison committee on *DSM-III*, American Psychoanalytic Society, 54–55, 64, 88
- managed healthcare: and drug treatments, 194, 197–98, 221*n*5; and DTC marketing, 112; escalating cost of, and psychoanalysis, 40
- manic disorder, 82
- Marill, Irwin, 45, 66, 70
- marketing, pharmaceutical: and diagnostic cycle, 123; direct-to-customer (DTC), 112, 132; by drug companies, 106–17, 196–97; guidelines and inventories for, 135–37; of medical conditions, 134–35; of Paxil, 117–19; of psychotropic drugs, 199–200; satire of, in *The Corrections*, 180–81; and social anxiety disorder, 4–5, 123, 130, 132, 137–38; and working environments, 129–30
- Marks, Isaac: on drug company advertising, 105; and *DSM-III* inclusion of social phobia, 71–75; *Fears and Phobias*, 12–13; and social anxiety, 7, 12–13, 28
- Marmor, Judd, 39, 41, 42, 52
- Marshall, John R., *Social Phobia: From Shyness to Stage Fright*, 135–36
- Masserman, Jules, 58, 59
- masturbation, 23, 24
- McCaulley, Mary, and introversion as mental disorder, 81–84
- McDowell, David, 149
- McElroy, Susan, 15

- medical insurance: and diagnostic criteria, 64; and *DSM* influence, 3; and psychoanalysis, 40, 221*n*5
- Medicare prescription drug bill, and PhRMA, 203
- melancholia, 22, 23, 32
- Menninger, Karl, 207
- mental disorders: acceptance of, and drug treatment, 194–202; alleged biological foundations of, 19–20, 21, 63–64, 205; definition and marketing of, 101–3; diagnostic criteria for, 56–58, 61–65; and *DSM* inclusion, 197, 204–5; and pharmaceutical companies, 104–6
- Meprospan (meprobamate), 106, 107
- Merck pharmaceutical company, 106
- Millon, Theodore, 43–44, 88, 89, 94, 95
- Miltown (meprobamate), 106
- Miner, Richard, 70
- Mintz, Morton, *The Therapeutic Nightmare*, 106–7
- monoamine oxidase inhibitors (MAOIs), 114, 233*n*26
- Moynihán, Ray, with Alan Cassels, *Selling Sickness*, 112, 123, 136
- Myers-Briggs Type Indicator, 82–83
- Nardil (phenelzine), 106, 114, 117
- National Comorbidity Survey (1990–92), 199, 201
- National Institute of Mental Health, and shyness as mental disorder, 6
- National Institutes of Health, and funding for IED research, 195
- neo-Kraepelinians, 25–26, 50, 63–64
- neuropsychiatrists: and brain chemistry, 20, 206–7; cultural backlash against, 172; and diagnostic criteria in *DSM*, 69–70, 134, 194, 197, 199, 204; and drug treatments, 149, 151, 153, 162, 167, 194–95, 204; and Emil Kraepelin, 24, 25; and “neurosis” as term, 52–53, 60, 65; views of anxiety, 141, 149, 151
- neuropsychiatry: biochemical focus of, 20, 159, 209; and complexity of selfhood, 210–11; and descriptive diagnosis, 35–36; and *DSM-III*, 46–47, 49–50, 60–61; and psychoanalysis, 28–35, 40; and psychodynamic therapy, 168; and social policy, 207. *See also* pharmacology; psychopharmacology
- neurosis: deletion from *DSM-III*, 48–49, 50–51, 52–53, 60, 73; as diagnostic term, 56–57, 58, 65
- neurotransmitters, in the brain, 2, 33, 147–48; 5-HT1A and 5-HT2 receptors, 147–48. *See also* cholinergic system; selective serotonin-reuptake inhibitors; serotonergic system; serotonin
- normal behavior: and introversion, 82–85; and psychiatric theory, 27–28, 32, 218–19*n*42
- obsessive compulsive disorder (OCD), 42, 53, 121, 159
- office-related anxiety, and pharmaceutical advertising, 129–30, 135, 149
- oppositional defiant disorder (ODD), 8, 67, 201
- Orwell, George, 1984, 8, 170
- panic disorder: and inclusion in *DSM-III*, 42, 74; marketing of Paxil for, 144, 153
- paranoia, and *DSM-II*, 38
- Pardes, Herbert, 60–61
- paroxetine. *See* Paxil (paroxetine hydrochloride)
- Parry, Vince, 134–35
- Paxil (paroxetine hydrochloride): and adequacy of treatment, 153; advertising and marketing of, 4–5, 105–6, 117–34, 136, 174; as anticholinergic, 146–47; FDA approval of, 120, 125, 139; fictional portrayal of, 187; as Paxil CR (“Controlled Release”), 121; for public speaking anxiety, 101, 204, 206; and rebound syndrome, 139–40, 142, 147–48; as Seroxat (UK name), 105, 116, 118, 119, 122; side effects of and withdrawal symptoms from, 7, 117–19, 120, 132–33, 139, 141–49, 167; as treatment for shyness, 6, 102–3, 204; as treatment for social anxiety disorder, 117, 121–34, 139
- Peele, Roger, 43, 51

- performance-enhancing drugs, 8, 209
- personality disorders, 8, 66–67, 78–79
- Pfizer pharmaceutical company, 135; and behind-the-scenes funding of charities and advocacy groups, 136–37; and marketing of Zoloft, 117, 137–38
- pharmaceutical companies. *See* drug companies
- Pharmaceutical Research and Manufacturers of America (PhRMA), 203–4
- pharmacological dystopia, and *Brave New World* (Huxley), 106, 169–70
- pharmacology, 188; cosmetic use of, 16–17, 101, 171–72, 195; and marketing of mental illness, 106–7, 134, 153; and psychiatry, 104. *See also* neuropsychiatry; psychopharmacology
- Phillips, Adam, 32, 155, 157, 160
- Pinsker, Henry, 64
- Plato, *Phaedrus*, 169, 181
- post-traumatic stress disorder (PTSD), 42, 120
- pregnancy complications, and anticholinergic SSRIs, 118, 120, 142
- premenstrual dysphoric disorder (PMDD): contentious history of, 228*n*41; and *DSM-V*, 195; first known as “Late Luteal Phase Dysphoric Disorder,” 82; marketing of Paxil and Prozac for, 121, 144, 173; and partial inclusion in *DSM-III-R* and *DSM-IV*, 80–81, 82, 135
- Propranolol (beta-blocker), 4–5
- Prozac (fluoxetine hydrochloride), 2, 105; fictional portrayal of, 186–87; *Listening to Prozac* (Kramer), 169–72, 177; as Sarafem, 173; side effects of, 167, 171, 240*n*8; as SSRI, 117, 121, 147, 167, 169–72; as treatment for intermittent explosive disorder (IED), 196
- psychiatry: biomedical focus of, 104, 208; and “cosmetic psychopharmacology” (Kramer), 171–72; credibility of, and reform, 204–6; and *DSM-III* diagnostic criteria, 18, 56–61, 195; historical references, 14–17; and medical insurance, 40, 221*n*5; as partner to pharmacology, 104, 114, 188, 194, 202; and psychoanalysis, 6, 34, 35–37, 40
- psychoanalysis: counterintuitive perspective on anxiety, 34–35, 36, 165–66, 168; with drug treatment, 107, 111; and *DSM* diagnostic criteria, 3; and *DSM-III* task force perspective, 3, 25–28, 46–56, 60–61, 65, 77, 86; European acceptance of, 37–38, 50; and medical insurance coverage, 40, 221*n*5; and neo-Kraepelinians, 25–26, 50, 63–64; and neuropsychiatry, 28–35, 40; and relationship with psychiatry, 6, 34, 35–37, 40, 104; and self-recrimination, 161–62; and treatment of anxiety, 33–34, 154–55, 167; and Wilhelm Reich, 41; and World Health Organization, 3, 37–38. *See also* Freud, Sigmund
- psychodynamic therapy: and diagnostic criteria, 53, 168; and drug treatment, 167; and perspective of *DSM-III*, 46–47
- psychopharmacologists: and drug treatment for depression and anxiety, 13–14; and medication of new disorders, 199
- psychopharmacology: cosmetic, 16–17, 101, 171–72, 195; and government-sponsored research, 37; and pre-Freudian theory, 27. *See also* neuropsychiatry; pharmacology
- psychotherapy: and cognitive-behavior theories, 141; in combination with drug treatment, 107, 111
- psychotropic drugs: and diagnostic criteria, 199–200; and human identity, 169–70
- public speaking anxiety: alternative responses to, 204–5; drug treatments for, 100, 123, 198, 204, 206; and social phobia/social anxiety disorder, 5, 100–101, 135–36, 160, 166–67. *See also* stage fright
- Public Speaking–Social Anxiety Center of New York, 136
- Quen, Jacques, 58
- Quenk, Naomi, 78

- Rankine, Claudia, *Don't Let Me Be Lonely*, 172
- Rauch, Jonathan, 207–8
- rebound syndrome (cholinergic rebound), and drug treatment, 139–41, 148. *See also* cholinergic system; Paxil
- Regier, Darrel, 197
- Reich, Wilhelm, 41
- renal failure, as side effect, and Paxil, 118, 120, 142
- Restak, Richard, 16
- reticence, drug treatment for, 102. *See also* introversion
- Rhône-Poulenc pharmaceutical company, 37
- road rage, 7, 202, 204. *See also* intermittent explosive disorder (IED)
- Robins, Eli, 61, 62
- Roche pharmaceutical company, 37
- Rockland, Larry, and psychodynamic contributions to *DSM-III*, 53, 54
- Roth, Martin, 72
- Roudinesco, Elisabeth, 153
- Rounsaville, Bruce, drawing of *DSM-III* creation, 39, 48
- Sabshin, Melvin, and *DSM-III*, 40–41, 42, 52
- Samson, biblical figure, and antisocial personality disorder, 15, 17
- Sandoz pharmaceutical company, 37, 112
- Santiago, Carlos, 91
- Sarafem. *See* Prozac
- Satel, Sally, with Christina Hoff Sommers, *One Nation under Therapy*, 201, 205, 245n37
- Saul, Helen, *Phobias*, 15
- schizoid, as term, 79, 81, 85, 86, 89, 91
- schizoid personality disorder (SPD), 163, 202; and avoidant personality disorder, 95; evolution of, in *DSM-III*, 9, 80–91, 97
- schizophrenia: and *DSM-II*, 38; and Emil Kraepelin, 21; and social phobia, 92, 93
- schizotypal disorders, 80
- Schwartz, Richard, 64
- scientific psychiatry, 21, 30
- Scott, Susie, on shyness, 116, 157–58, 163, 207, 209
- selective serotonin-reuptake inhibitors (SSRIs), 33, 117, 171; and cholinergic system, 146–48; and cosmetic psychopharmacology, 101, 195; FDA approval of, 118; as medication for children, 151, 198–99; for routine conditions, 204, 209; and selfhood, 170–71; side effects of, 101, 118, 151, 153, 167, 171, 238n28; versus MAOIs, 114, 233n26. *See also* antidepressants; Paxil (paroxetine hydrochloride); serotonergic system; serotonin
- Self, Will: *Dr. Mukti and Other Tales of Woe*, 9, 188–93; *The Quantity Theory of Insanity*, 188, 191–92; *The Sweet Smell of Psychosis*, 188
- self-mutilation, and SSRIs, 118
- sensitive personality disorder, 67
- Serentil (mesoridazine), 112
- serotonergic system, and 5-HT1A and 5-HT2 receptors, 147–48, 151
- serotonin: and alleged links to depression and anxiety, 13–14; deficiency of, and marketing of Paxil, 123; and SSRIs, 147–49
- Seroxat. *See* Paxil (paroxetine hydrochloride)
- sexual dysfunction, and SSRIs, 147, 238n28
- Shaffer, David, 44, 45, 52
- Shepherdson, Charles, 34
- Shergold, Adrian, *Dirty Filthy Love* (film), 159
- shyness: advocacy and support groups for, 136–37; cultural views of, and selfhood, 8–9, 17–18, 207–11; and *DSM-III*, 47; interpretive history of, 11–16; medication for, 16–17, 102–3, 121, 139, 204; as social anxiety, 4, 18, 122, 157–59. *See also* introverted personality disorder (IPD); social anxiety disorder; social phobia
- Shyness Institute of Palo Alto, 5, 136

- Shyness Research Institute, Indiana University Southeast, 136
- side effects: of drugs for anxiety disorders, 141–49; of Paxil in particular, 117–19, 120, 132–33, 167; of SSRIs in general, 101, 151, 153, 167, 171, 238n28
- Slater, Eliot, 72
- Slater, Lauren, 147
- Smith, Kline and French pharmaceutical company, 37. *See also* GlaxoSmithKline; SmithKline Beecham
- Smith, Mikey, *Social History of the Minor Tranquilizers*, 106
- SmithKline Beecham pharmaceutical company: marketing of Paxil by, 7, 103, 105–6, 117–34, 136; and social phobia campaign, 98; support groups and diagnostic quizzes of, 135–37. *See also* GlaxoSmithKline; Smith, Kline and French
- social anxiety, 1, 2, 72, 198
- social anxiety disorder (SAD): alleged biological origins of, 19–20; and introversion, 83; marketing of drugs for, 104–5, 116–19, 120–21, 137–38; marketing of Paxil in particular for, 105–6, 121–34; overlap with avoidant personality disorder, 96; therapy for, 162–65, 166; threshold for, 4, 200. *See also* social phobia
- Social Anxiety Disorder Coalition, 126
- social phobia, 8, 9, 207; as anxiety disorder, 6, 19, 160–68; cultural views of, 12, 15, 17–18; diagnostic criteria for, 65, 78, 92–93, 99–100, 102; and *DSM-III*, 7, 42, 50, 56, 64, 71–78, 104, 208; and *DSM-III-R*, 96–101; fictional view of, 193; and pharmaceutical market, 98, 120–21, 135–36, 144; and Pierre Janet, 30; renamed in 1987 as social anxiety disorder, 97–100; statistical percentages for, 213m, 244n35; treatment and therapy for, 153, 160–68. *See also* social anxiety disorder
- social policy, and neuropsychiatry, 207
- social services, and *DSM* influence, 3
- solitude, 8–9, 114
- Sommers, Christina Hoff, with Sally Satel, *One Nation under Therapy*, 201, 205, 235n37
- Spiegel, Alix, 51
- Spitzer, Eliot, as attorney general, New York, 146
- Spitzer, Robert L.: as chair, *DSM-III* task force, 6–7, 38, 39–46; and *DSM* creation of categories, 79–82; and *DSM* diagnostic criteria, 56–70; and *DSM-II*, 37–38, 41–42; and *DSM-III-R*, 96, 97–101; and *DSM* neuropsychiatry framework, 46–51, 60, 194–95; inclusion of social phobia in *DSM-III*, 71–78; and introversion as personality disorder, 78–79, 82–97; and psychodynamic contributions to *DSM-III*, 51–56
- Spivak, Kenin, 103
- stage fright, 12. *See also* public speaking anxiety
- statistical accuracy, and proliferation of *DSM* categories, 42–44, 68–70
- Stein, Murray, 5, 101–3, 104
- Stevenson, Robert Louis, *Strange Case of Dr. Jekyll and Mr. Hyde*, 169
- Stone, Allan, 58
- suicide ideation, as side effect of SSRIs, 118, 119, 142, 144, 198
- superego, and Freudian theory, 160–61
- support groups, sponsorship and funding of, 136–37
- Szasz, Thomas S., *The Myth of Mental Illness*, 233n27
- Talbot, Margaret, 209
- Tauzin, W. J. “Billy,” and PHMA, 203, 204
- thalidomide, 206
- Thoreau, Henry David, 8–9
- Thucydides, *History of the Peloponnesian War*, 16
- Upjohn pharmaceutical company, and conference on panic disorder, 74, 75
- U.S. Congress: Medicare prescription drug bill, 203; and pharmaceutical advertising, 111–12, 114

- Vaillant, George, 66
 Valenstein, Elliot, 19–20
 Valium (diazepam), 106
 Vedantam, Shankar, 101
 Viagra (sildenafil citrate), 135
 Viner, Michael, 203–4
- Walker, Leonore, 45
 Warner pharmaceutical company, 114, 117
 Washington University, department of psychiatry, and Feighner criteria, 62, 63
 Waugh, Robert, 45–46
 Westphal, Carl, 30, 32
 Will, Otto Allen, 78, 83–84
 William, Ricky, 132–33
 Wilson, Mitchell, 57
- withdrawal symptoms, and Paxil, 117, 118, 120, 141–49
 withdrawn, as term, 87
 withdrawn personality disorder, 67
 World Health Organization: and *ICD*, 3, 41; and *ICD-8*, 37–38; and mental-health policy, 200
 Wurtzel, Elizabeth, *Prozac Nation*, 182
- Xanax (alprazolam), 74
- Zantac (ranitidine hydrochloride), 135
 Zimbardo, Philip, 5
 Zoloft (sertraline hydrochloride), 2, 105, 121, 147; marketing of, 117, 137–38; as treatment for intermittent explosive disorder, 196; as treatment for shyness, 6, 102, 137–38